Belgium announced on Saturday the deployment for adults of the Johnson & Johnson vaccine after the conclusions of the European Medicines Agency (EMA) considering that it benefited from a favorable benefit / risk ratio despite a "
very rare
"
risk
of clots blood.
Read also: Europe's green light for Johnson & Johnson vaccine
The AstraZeneca vaccine will be used for people aged 41 and over, against 56 and over so far, the EMA having concluded "
that the risk of serious Covid-19
" was "
overall much higher than that of 'serious side effects
', according to the press release from the Belgian authorities.
36,000 doses of Johnson & Johnson already delivered
The formation of blood clots with the AstraZeneca vaccine "
occurs only in very rare cases, and mainly in young people
", they recall, stressing that from the age of 41, the benefits "
largely
outweighed
the rare risks
”.
Read also: Coronavirus: those who love (the absurd) in Belgium will take the train (during the holidays)
Regarding the Johnson & Johnson vaccine, of which Belgium has already received 36,000 doses, vaccination will begin "as
soon as possible
".
A total of 1.4 million doses of this vaccine should be delivered to Belgium between April and June.
